Abstract
Early non-invasive and reliable biomarkers are among the major unmet needs in Parkinson’s disease (PD), in order to monitor therapy response and disease progression. Technology-based objective measures of motor performances could allow a deeper phenotyping of early stage motor changes which could be useful to identify frailer PD patients. Our aim is to identify early prognostic biomarkers in newly diagnosed PD patients and objectively quantify therapy-response.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
